In contrast to skeletal muscle, which is targeted for degradation by the muscle-specific E3 ubiquitin ligases MuRF1 and Atrogin1/MAFbx [4], no upregulation of either of these E3 ligases was detected in human visceral SMCs treated with tumor organoid factors from cachectic pancreatic cancer patients. This evidence concerns the gene FBXO32 and neoplasm.